Multicenter study demonstrates survival benefit of immunochemotherapy in advanced biliary tract cancer, suggesting key role of patient selection.
In this real-world cohort, the survival benefit of GCD appeared to be primarily observed in patients meeting TOPAZ-1 eligibility criteria. Trial-based eligibility may influence the magnitude of benefit from immunochemotherapy in advanced BTC, underscoring the importance of patient selection in routine practice.
No takes yet. Share an insight, caveat, or question.
Kosaka et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: